Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer

Cell Biochemistry and Biophysics

Volumn 72, Issue 2, 2015, Pages 471-473

  Wang, Xin ^a   Wang, Lei ^a   Wang, Huayong ^a   Zhang, Hao ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Chemotherapy; Nausea vomiting; Non small cell lung cancer; Olanzapine; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; DRUG COMBINATION; OLANZAPINE; ONDANSETRON;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; VOMITING;

EID: 84930866047     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-0489-0     Document Type: Article

References (14)

1. Robert, J., Ginsberg, H. J., & Lung, C. (2010). American Cancer Society Clinical Oncology Series (pp. 1–7). Beijing: China Medical Science and Technology Press.
2. Wiser, W., & Berger, A. (2005). Practical management of chemotherapy-induced nausea and vomiting. Oncology,05, 637–645.
3. Shi, Y. K. (2008). Diagnosis and treatment of lung cancer (pp. 240–271). Beijing: People’s Health Publishing House.
4. Lin, C. (2011). Management of the toxicities of anti-cancer drugs. Programme for Japanese Medicine, 11, 491–493.
5. Gregory, R.E., Ettinger, D.S. (1998). 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. Drugs, 2, 173–189.
6. Zhang, X.J., Zhang, P. (2009). Advances in mechanism and treatment of chemotherapy-induced nausea and vomiting. Oncology Programme, 4(4), 348–354.
7. Ma J, Han ZX. (2010). Hemotherapy-induced nausea and vomiting: research advances and management. Journal of Xuzhou Medical College. doi:10.3969/j.issn.1000-2065.2010.09.024.
8. Navari, R. M., Gray, S. E., & Kerr, A. C. (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase Trial. Journal of Support Oncology,9(5), 188–195.
9. Passik, S. D., Kirsh, K. L., & Theobald, D. E. (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. Journal of Pain Symptom Management,25(5), 485–488.
10. Bymaster F, Perry KW, Nelson DL (1999) Olanzapine: a basic science update. British Journal of Psychiatry Supplement,37, 36–40.
11. He, H., & Richardson, J. S. (1995). A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptor. International Clinical Psychopharmacology,10(1), 19–30.
12. Schotte, A., Janssen, P. F., & Gommeren, W. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology,124(1–2), 57–73.
13. Jordan, K., Kasper, C., & Schmoll, H. J. (2005). Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. European Journal of Cancer,4(2), 199–205.
14. Navari, R. M. (2006). Ondansetron, prochlorperazine, and dexamethasone have similar effects on prevention of delayed chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews,32(1), 50–54.